CRIS, Curis (formerly CBMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI)

CRIS 1.430

+10.9%

Nov 6 3:57 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (544)	5/4/2005 12:45:57 PM
From: Jim Oravetz	of 668

FDA Acceptance Of Application To Initiate Skin Cancer Phase I Clinical Trial DOW JONES NEWSWIRES May 4, 2005 10:03 a.m. CAMBRIDGE, Mass. -- Curis Inc. (CRIS) said an Investigational New Drug application filed by its collaborator Genentech Inc. (DNA) has been accepted by the U.S. Food and Drug Administration. In a press release, Curis said this acceptance provides approval for Genentech to initiate a Phase I clinical trial of a drug candidate for the topical treatment of basal cell carcinoma. Basal cell carcinoma is the most common form of all human cancers with about 800,000 to 1 million new cases reported every year in the U.S., it said. This drug candidate is an antagonist of the Hedgehog signaling pathway that was discovered by Curis and is being co-developed through a collaboration between Genentech and Curis, the company noted. Curis is a therapeutic drug development company. Genentech, San Francisco, is a biotechnology company. Company Web Sites: curis.com and gene.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next